LAG3 and neoplasm: However, our understanding of LAG-3 is very limited, and many questions remain to be explored: (1) down-regulation of T cell signaling pathways, connectivity among numerous ligands, and synergistic mechanism exploration with other immunoassays; (2) Whether LAG-3 can be combined with other therapeutic modalities, including chemotherapy, targeted therapy, and interventional therapy, to improve the effectiveness of tumor therapy; (3) Why LAG-3 is less effective than PD-1 under different signal transduction.